Radiopharmaceutical Sales

Radiopharmaceutical Sales Market Outlook

The global radiopharmaceutical sales market is projected to reach approximately USD 8.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 9.5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing incidence of cancer and neurological disorders, which has heightened the demand for advanced diagnostic and therapeutic solutions. Additionally, technological advancements in imaging techniques and radiopharmaceutical development are expected to further bolster market expansion. Furthermore, the rise in geriatric populations and the growing prevalence of chronic diseases are driving the need for more effective treatment options. The increasing awareness regarding the benefits of nuclear medicine and its applications in various medical fields also contributes to the market's growth.

Growth Factor of the Market

The radiopharmaceutical sales market is experiencing robust growth due to several factors, including an increasing number of diagnostic and therapeutic procedures utilizing radiopharmaceuticals. Advances in nuclear medicine, specifically the development of targeted therapies and new imaging agents, are enhancing the effectiveness and safety of treatments. The rise in cancer prevalence globally has necessitated the need for effective diagnostics and targeted therapies, which radiopharmaceuticals provide. Furthermore, collaborations between pharmaceutical companies and research institutions are fostering innovation in this field, leading to the introduction of novel radiopharmaceutical products. The expanding healthcare infrastructure in emerging economies also plays a vital role in driving the demand for these medical products, as improved access to healthcare facilities increases the utilization of radiopharmaceuticals for diagnosis and treatment.

Key Highlights of the Market

• The market is expected to witness a CAGR of 9.5% from 2025 to 2035, driven by technological advancements.
• Oncology applications hold the largest market share due to an increasing number of cancer cases.
• North America remains the dominant region, accounting for a significant portion of market revenue.
• Technetium-99 is the most widely used isotope, prominently featured in diagnostic procedures.
• Growth in online pharmacies is transforming distribution channels for radiopharmaceuticals.

By Product Type

Diagnostic Radiopharmaceuticals:

Diagnostic radiopharmaceuticals are critical in the medical imaging domain, enabling healthcare professionals to visualize and assess various physiological functions. These agents are typically used in techniques such as Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). The increasing prevalence of diseases such as cancer, cardiovascular disorders, and neurological conditions contributes significantly to the demand for diagnostic radiopharmaceuticals. Furthermore, advancements in imaging technology have facilitated the development of more effective diagnostic agents, which allows for improved patient outcomes. As healthcare systems increasingly adopt advanced imaging modalities, the market for diagnostic radiopharmaceuticals is expected to grow, driven by the need for accurate and timely diagnostics.

Therapeutic Radiopharmaceuticals:

Therapeutic radiopharmaceuticals are utilized to treat various diseases, particularly cancer, by delivering targeted radiation to specific tissues. These products have gained traction due to their ability to minimize damage to surrounding healthy tissues while providing effective treatment. The growing prevalence of cancer and the demand for personalized medicine are substantial drivers for this segment. Additionally, the continuing research into new therapeutic agents and the approval of novel therapies are enhancing the development pipeline. The advancement of targeted alpha therapy and beta therapy is also expected to influence market growth, providing innovative treatment options for patients with difficult-to-treat conditions, ultimately leading to an expansion in the therapeutic radiopharmaceutical market.

By Application

Oncology:

Oncology remains the leading application for radiopharmaceuticals, driven by the rising incidence of various cancers globally. Radiopharmaceuticals offer unique advantages in cancer diagnosis and treatment, including the ability to target tumors specifically and monitor therapeutic responses. The increasing adoption of precision medicine approaches in oncology is further enhancing the utilization of radiopharmaceuticals. The ability to visualize tumors using PET scans and subsequently administer targeted radiotherapy has revolutionized cancer care. Additionally, ongoing clinical trials are continuously evaluating radiopharmaceuticals for new indications, which is expected to further propel growth in this segment. As the demand for effective cancer treatments continues to rise, the oncology application segment will likely remain a key driver for the radiopharmaceutical sales market.

Cardiology:

The cardiology segment demonstrates significant growth potential as radiopharmaceuticals are essential in diagnosing and managing cardiovascular diseases. Agents used in myocardial perfusion imaging enable clinicians to assess blood flow to the heart and identify conditions such as coronary artery disease. The increasing prevalence of heart-related conditions, coupled with advancements in imaging technology, has led to heightened demand for cardiology-related radiopharmaceuticals. Innovations such as hybrid imaging techniques that combine functional and anatomical imaging are improving diagnostic accuracy. These developments are further cementing the role of radiopharmaceuticals in cardiology, making this application a critical component of the overall market.

Neurology:

The neurology application segment for radiopharmaceuticals is gaining traction, fueled by the rising prevalence of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, and epilepsy. Radiopharmaceuticals used in neuroimaging, such as FDG-PET, allow for the visualization of brain metabolism and function, providing valuable insights into neurological diseases. As research into neurodegenerative disorders expands, the demand for radiopharmaceuticals in this application area is expected to grow. Moreover, the integration of advanced imaging technologies with radiopharmaceuticals is enhancing diagnostic capabilities, leading to better patient management and treatment outcomes in neurology. This growing recognition of the importance of early diagnosis and intervention will likely drive the neurology segment's growth within the radiopharmaceutical market.

Endocrinology:

The endocrinology segment of the radiopharmaceutical market is emerging, supported by the increasing incidence of endocrine disorders, particularly thyroid diseases. Radiopharmaceuticals such as Iodine-131 are widely used in the diagnosis and treatment of thyroid conditions, including hyperthyroidism and thyroid cancer. The growing awareness of the importance of early detection and treatment options for endocrine disorders contributes to market growth. Furthermore, advancements in radiopharmaceutical technology and the increasing penetration of nuclear medicine into routine clinical practice are expanding the application of radiopharmaceuticals in endocrinology. As more healthcare providers recognize the benefits of these products, the endocrinology segment is expected to witness significant growth in the coming years.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for radiopharmaceuticals, accounting for a significant share of the market. These healthcare institutions are equipped to handle complex procedures involving radiopharmaceuticals, including diagnostics and therapeutic applications. The increasing number of hospitals adopting advanced imaging systems and nuclear medicine departments is contributing to the growth of this channel. Hospitals are also pivotal in providing comprehensive care, including patient management and follow-up after radiopharmaceutical administration. The growing preference for outpatient procedures and advancements in healthcare infrastructure are expected to drive the demand for radiopharmaceuticals through hospitals in the coming years.

Diagnostic Centers:

Diagnostic centers are becoming increasingly popular as a distribution channel for radiopharmaceuticals due to their specialization in imaging and diagnostic services. These centers are equipped with advanced imaging technologies and expertise, facilitating the efficient use of radiopharmaceuticals for diagnostic purposes. The rising demand for timely and accurate diagnostics is propelling the growth of diagnostic centers, as they offer patients convenience and quicker results compared to traditional hospital settings. Furthermore, the collaboration between diagnostic centers and pharmaceutical companies is enhancing the availability of radiopharmaceuticals, making them more accessible to patients. As the trend towards early detection of diseases continues, diagnostic centers will play a crucial role in the radiopharmaceutical sales market.

Research Institutes:

Research institutes are essential players in the distribution channel for radiopharmaceuticals, primarily focusing on the development and clinical evaluation of new products. These institutions often collaborate with pharmaceutical companies and healthcare providers to conduct clinical trials that test the efficacy of novel radiopharmaceuticals. The increasing investment in research and development for innovative radiopharmaceutical agents is driving growth in this channel. Research institutes are pivotal in generating data necessary for regulatory approvals, which ultimately translates into market availability for new products. The ongoing research into radiopharmaceutical applications is expected to enhance their adoption and further propel the market.

Online Pharmacies:

Online pharmacies are emerging as a significant distribution channel for radiopharmaceuticals, driven by the rise of e-commerce and the increasing demand for convenient access to medications. The growing trend towards digital healthcare solutions and telemedicine is shaping consumer behavior, leading patients and healthcare practitioners to seek online solutions for procurement. Online pharmacies provide a platform for patients to obtain radiopharmaceuticals with minimal hassle, enhancing accessibility, especially in remote areas. Moreover, the regulatory framework surrounding online pharmacies is evolving to ensure safe distribution practices for radiopharmaceuticals. This segment is poised for growth as more consumers become comfortable purchasing medications online, contributing to the overall radiopharmaceutical sales market.

Others:

Other distribution channels for radiopharmaceuticals include specialty pharmacies and compounding pharmacies that cater to specific patient needs. These channels provide tailored services and products, allowing for personalized treatments that may not be available through conventional distribution methods. The increasing demand for customized healthcare solutions is driving growth in this segment. Furthermore, these specialty channels are equipped to handle the complexities of radiopharmaceuticals, ensuring that they are stored and administered correctly. As the focus on personalized medicine intensifies, the importance of these alternative distribution channels will likely increase, contributing to the overall market dynamics.

By Ingredient Type

Technetium-99:

Technetium-99 is the most widely used radiopharmaceutical in diagnostic imaging, primarily due to its favorable physical properties and availability. It plays a crucial role in SPECT imaging, enabling healthcare providers to visualize various organ functions, including cardiac and skeletal systems. The wide range of technetium-based radiopharmaceuticals enhances its application in clinical practices, making it a cornerstone in nuclear medicine. The continuous advancements in production techniques further enhance the availability and efficiency of technetium-99, ensuring its sustained dominance in the market. As healthcare systems increasingly rely on nuclear medicine for effective diagnostics, technetium-99 will continue to hold a leading position in the radiopharmaceutical ingredient segment.

Iodine-131:

Iodine-131 is a key ingredient predominantly utilized in the treatment of thyroid disorders, particularly thyroid cancer and hyperthyroidism. Its efficacy in selectively targeting thyroid tissues makes it a preferred choice for clinicians. The growing incidence of thyroid-related diseases, combined with rising patient awareness, has propelled the demand for Iodine-131 in therapeutic applications. Moreover, advances in radiotherapeutic techniques are improving treatment outcomes for patients, further solidifying the role of Iodine-131 in clinical practice. As the emphasis on effective and targeted treatment options continues to rise, Iodine-131 is expected to remain a critical component of the radiopharmaceutical ingredient landscape.

Gallium-68:

Gallium-68 is increasingly recognized for its role in PET imaging, particularly in the diagnosis of neuroendocrine tumors and other malignancies. The ability of Gallium-68 to bind to specific receptors enhances its utility in targeted imaging, allowing for accurate assessments of tumor activity. The growing prevalence of neuroendocrine tumors and the demand for precise diagnostic tools are driving the adoption of Gallium-68. Additionally, advancements in production methods and the establishment of radiopharmaceutical production facilities are improving the availability of Gallium-68, contributing to its market growth. As the field of molecular imaging evolves, Gallium-68 is poised to play a significant role in the future of radiopharmaceuticals.

Fluorine-18:

Fluorine-18 is a prominent radiopharmaceutical used primarily in PET imaging, particularly in oncology. Its short half-life and effective imaging capabilities make it ideal for assessing various malignancies and monitoring treatment responses. The increasing incidence of cancer and the demand for advanced imaging techniques are driving the growth of Fluorine-18 in the market. Moreover, the development of novel Fluorine-18-labeled compounds is expanding its application scope and enhancing diagnostic precision. As PET imaging continues to gain traction as a critical component of cancer care, Fluorine-18 will remain a vital ingredient in the radiopharmaceutical landscape, supporting improved patient outcomes through accurate and timely diagnostics.

By Region

The North American radiopharmaceutical sales market dominates the global landscape, accounting for over 40% of the total market share. This region's advanced healthcare infrastructure, coupled with significant investments in research and development, facilitates the rapid adoption of radiopharmaceuticals. The increasing incidence of cancer and cardiovascular diseases, along with the growing preference for early diagnosis, drive the demand for radiopharmaceuticals in North America. Furthermore, the presence of numerous key players and a robust regulatory framework support the market's growth. The CAGR for the North American region is projected to be around 9.2%, reflecting its leadership in the radiopharmaceutical sector.

Europe follows North America as a substantial market for radiopharmaceuticals, holding a share of approximately 30%. The region experiences an increasing prevalence of chronic diseases, which is propelling the demand for effective diagnostic and treatment options. Additionally, the European healthcare system's focus on improving patient outcomes through advanced diagnostics is positively impacting the market. Emerging economies within the Asia Pacific region are also expected to witness significant growth, with a projected CAGR of around 10% during the forecast period. This growth is attributed to the rising healthcare expenditure, increased awareness of nuclear medicine, and the expansion of healthcare infrastructure in countries like India and China. As such, the regional landscape for radiopharmaceuticals is characterized by significant opportunities and challenges that will shape the market's future.

Opportunities

The radiopharmaceutical sales market holds numerous opportunities, particularly in emerging markets where the healthcare infrastructure is rapidly evolving. Countries in Asia Pacific, Latin America, and parts of the Middle East & Africa are witnessing substantial investments in healthcare facilities and nuclear medicine departments. These investments create opportunities for the introduction and adoption of radiopharmaceuticals, particularly as the demand for advanced diagnostics and targeted therapies increases. Furthermore, the growing emphasis on personalized medicine is expected to drive the development of innovative radiopharmaceutical products tailored to individual patient needs. As healthcare providers seek effective solutions for complex diseases, the market can capitalize on these trends by expanding its product offerings and enhancing distribution networks to meet rising demand.

Moreover, collaborations between pharmaceutical companies, healthcare providers, and research institutions present a significant opportunity for growth in the radiopharmaceutical market. Joint ventures focused on the development of novel agents and imaging techniques can lead to breakthroughs that enhance the efficacy and safety of treatments. The integration of artificial intelligence and machine learning in nuclear medicine is also a promising area for future growth, as these technologies can streamline radiopharmaceutical development, improve imaging accuracy, and optimize treatment outcomes. By leveraging these collaborations and technological advancements, the market can position itself for success in a rapidly evolving healthcare landscape.

Threats

The radiopharmaceutical market faces several threats that could hinder its growth, particularly the stringent regulatory environment governing the development and use of these medical products. Regulatory bodies, such as the FDA and EMA, impose rigorous requirements for the approval of radiopharmaceuticals, which can delay product launches and increase costs for manufacturers. The complexity of the approval process and the need for extensive clinical trials can pose significant challenges for smaller companies looking to enter the market. Additionally, the potential for adverse effects or complications associated with the use of radiopharmaceuticals can impact patient acceptance and limit their utilization, posing a threat to market growth.

Supply chain disruptions present another threat to the radiopharmaceutical market, particularly given the reliance on specific isotopes that have limited availability. Any disruptions in the production or distribution of these isotopes can lead to shortages and impact the ability of healthcare providers to deliver timely diagnostics and treatment. Furthermore, competition from alternative imaging techniques, such as MRI and CT, can challenge the radiopharmaceutical market as healthcare providers may opt for these methods due to their widespread availability and lower regulatory hurdles. Addressing these threats will require strategic planning and collaboration among stakeholders in the radiopharmaceutical ecosystem.

Competitor Outlook

• GE Healthcare
• Siemens Healthineers
• Cardinal Health
• Philips Healthcare
• Novartis AG
• Bayer AG
• Bracco Imaging S.p.A.
• Alliance Medical
• RadioMedix
• Advanced Accelerator Applications (AAA)
• Lantheus Medical Imaging
• Iba RadioPharma Solutions
• NorthStar Medical Radioisotopes
• Jubilant DraxImage
• Curium Pharma

The competitive landscape of the radiopharmaceutical sales market is characterized by a mix of large multinational corporations and specialized companies focused on niche markets. Major players like GE Healthcare and Siemens Healthineers leverage their extensive resources and technological advancements to dominate the market, offering a wide range of diagnostic and therapeutic radiopharmaceuticals. These companies continually invest in research and development to innovate their product offerings, ensuring they stay ahead in an increasingly competitive environment. Additionally, their strong distribution networks and established relationships with healthcare providers give them a significant advantage in market penetration.

On the other hand, specialized companies such as RadioMedix and Advanced Accelerator Applications focus on developing unique radiopharmaceutical products catering to specific medical applications, such as targeted therapies and advanced imaging techniques. These firms often engage in strategic partnerships and collaborations with research institutions and healthcare providers to enhance their product portfolios and expand market reach. As the demand for personalized medicine and precision diagnostics grows, these specialized firms are well-positioned to capitalize on emerging opportunities in the radiopharmaceutical space.

Furthermore, the market is witnessing an influx of new entrants, particularly from emerging economies, seeking to develop and commercialize innovative radiopharmaceutical products. This trend is driven by the increasing demand for advanced healthcare solutions and the growing awareness of nuclear medicine's potential. These new players often bring fresh ideas and innovative technologies to the market, fostering competition and driving overall market growth. As the radiopharmaceutical sales market continues to evolve, it will be essential for established companies to monitor emerging trends and adapt their strategies to stay relevant in a dynamic landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Bayer AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 RadioMedix
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Curium Pharma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 GE Healthcare
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Cardinal Health
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Alliance Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Jubilant DraxImage
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Philips Healthcare
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bracco Imaging S.p.A.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Lantheus Medical Imaging
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Iba RadioPharma Solutions
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 NorthStar Medical Radioisotopes
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Advanced Accelerator Applications (AAA)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Radiopharmaceutical Sales Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Cardiology
    • 6.1.3 Neurology
    • 6.1.4 Endocrinology
    • 6.1.5 Others
  • 6.2 Radiopharmaceutical Sales Market, By Product Type
    • 6.2.1 Diagnostic Radiopharmaceuticals
    • 6.2.2 Therapeutic Radiopharmaceuticals
  • 6.3 Radiopharmaceutical Sales Market, By Ingredient Type
    • 6.3.1 Technetium-99
    • 6.3.2 Iodine-131
    • 6.3.3 Gallium-68
    • 6.3.4 Fluorine-18
    • 6.3.5 Others
  • 6.4 Radiopharmaceutical Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Centers
    • 6.4.3 Research Institutes
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Radiopharmaceutical Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Radiopharmaceutical Sales market is categorized based on

By Product Type

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals

By Application

• Oncology
• Cardiology
• Neurology
• Endocrinology
• Others

By Distribution Channel

• Hospitals
• Diagnostic Centers
• Research Institutes
• Online Pharmacies
• Others

By Ingredient Type

• Technetium-99
• Iodine-131
• Gallium-68
• Fluorine-18
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Siemens Healthineers
• Cardinal Health
• Philips Healthcare
• Novartis AG
• Bayer AG
• Bracco Imaging S.p.A.
• Alliance Medical
• RadioMedix
• Advanced Accelerator Applications (AAA)
• Lantheus Medical Imaging
• Iba RadioPharma Solutions
• NorthStar Medical Radioisotopes
• Jubilant DraxImage
• Curium Pharma